Factsheets on COVID-19 Vaccines
In partnership with the Asian Development Bank, IVAC developed factsheets summarizing key measures for COVID-19 vaccines such as effectiveness and protection against severe disease.
The factsheets include:
- Duration of Protection of COVID-19 Vaccines against Omicron
- Effectiveness of COVID-19 mRNA Vaccines Against Omicron
- Effectiveness of COVID-19 Inactivated Vaccines Against Omicron
Duration of Protection of COVID-19 Vaccines against Omicron (November 2022)
Key Facts:
- COVID-19 vaccines work less well against Omicron than other variants
- Vaccine protection against symptomatic disease drops quickly
- Protection against severe disease, like hospitalization and ICU admission, is better and durable for many months
- A booster shot substantially improves protection against Omicron infection and disease
- Booster protection against severe disease lasts for many months
- Booster protection against symptomatic disease declines quickly
Effectiveness of COVID-19 mRNA Vaccines Against Omicron (November 2022)
Key Facts:
- COVID-19 mRNA vaccines are highly effective but are less effective against Omicron than other variants
- After the primary mRNA vaccination series:
- Protection against Omicron symptomatic disease (disease of any severity) drops quickly
- Protection against severe disease is better than that for symptomatic disease and declines some over many months
- After a booster shot (3rd dose) of mRNA vaccine:
- Protection against Omicron symptomatic disease improves substantially but then drops quickly
- Protection against Omicron severe disease improves to >80% on average and declines some over many months.
- COVID mRNA vaccines are safe and severe adverse reactions are rare:
- Myocarditis has been detected after mRNA vaccination in rare cases mostly in boys 12-15 years
- Bell’s Palsy is possibly associated with mRNA vaccines.
Effectiveness of COVID-19 Inactivated Vaccines Against Omicron (November 2022)
Key Facts:
- COVID-19 inactivated vaccines protect against severe disease, but poorly protects against infection with Omicron.
- Effectiveness of the primary vaccination series:
- Protection against Omicron symptomatic disease (of any severity) is low.
- Protection against Omicron severe disease is better than for symptomatic disease and lasts for many months.
- After a booster shot (3rd dose) of an inactivated vaccine:
- Protection against Omicron symptomatic disease remained LOW with a booster dose of inactivated vaccine.
- Protection against Omicron severe disease improves to >70% and lasts for several months.
- After a booster shot with an mRNA vaccine:
- Protection against Omicron severe disease and symptomatic disease improved substantially but drops quickly for symptomatic disease.